Development Of Nanoparticles Of The Poorly Soluble Anti-Diabetic Drug (Pioglitazone) Drug
Main Article Content
Abstract
Diabetes mellitus is a pervasive metabolic disorder that poses a substantial global health burden. The treatment of Type 2 Diabetes (T2D), characterized by insulin resistance and impaired glucose metabolism, often involves the use of oral anti-diabetic medications. The encapsulation of PGZ within nanoparticles provides an opportunity to achieve controlled drug release, targeted delivery, enhanced therapeutic outcomes and enhancing PGZ solubility lies in the potential for improved therapeutic efficacy, dose reduction, enhanced patient compliance, and targeted drug delivery. The objective of this study was to prepare and evaluate poorly soluble anti-diabetic pioglitazone nanoparticles using tween 80, poloxamer 188 by emulsification technique. Pioglitazone is the first-line drug for the treatment of type II diabetes mellitus belongs to Biopharmaceutical Classification System Class II. The practically water-insoluble PGZ was nanoground by using nanosuspension by precipitation method. Tween 80 Emulsifier surface active agents were tested for their stabilizing effects. Different concentration of surfactant such as Tween 80 and ethanol: distilled water aqueous phase combination of surfactant was used for preparation of PGZ nanosuspension. The mean particle diameter of prepared nanoparticles ranged from 98.25to 150.55µm, zeta potential ranged from 22.13 to 30.60mV. The Yield Percentage (%) of these nanoparticles varies between 77.01 to 92.43%. The nanoparticles of PGZ Swelling Index were found to be in the range 0.855 to 2.887 and was % Drug loading 82.16 to 95.61 respectively. The results of evaluation analysis showed that particle size measurement, zeta potential and Yield Percentage. The outcomes of this research hold promise for revolutionizing PGZ therapy, offering an avenue to enhance its solubility and bioavailability, and ultimately improve patient outcomes and quality of life. The results of this study confirmed the sustained drug release profile of PGZ nanoparticles.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
International Diabetes Federation (IDF). IDF Diabetes Atlas, 9th ed. Brussels, Belgium: International Diabetes Federation, 2019.
Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-1576.
Sirtori CR. The pharmacology of statins. Pharmacological Research. 2014;88:3-11.
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics. 2008;5(4):505-515.
Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Letters. 2010;10(9):3223-3230.
Dressman J, Butler J. Drug delivery and targeting: For pharmacists and pharmaceutical scientists. CRC Press, 2001.
Mu H, Holm R, Müllertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. International Journal of Pharmaceutics. 2013;453(1):215-224.
Yousaf AM, Kim DW, Oh YK. Formulation of solid lipid nanoparticles for delivery of siRNA. European Journal of Pharmaceutics and Biopharmaceutics. 2010;75(3):310-321.
Teixeira MC, Carbone C, Souto EB. Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery. Progress in Lipid Research. 2017;68:1-11.
Lobo ED, Balthasar JP. Pharmacokinetic–pharmacodynamic modeling of methotrexate-induced toxicity in mice. Journal of Pharmaceutical Sciences. 2003;92(9):1805-1817.
Gajendiran M, Kumar DS, Murugesan R, Kandasamy R. Preparation and in vitro–in vivo evaluation of solid lipid nanoparticles of pioglitazone hydrochloride. Journal of Advanced Pharmaceutical Technology & Research. 2013;4(2):107-113.